Nemolizumab: where the agencies disagree
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
CIPM (Spain), DMC (Denmark) and HIRA (South Korea), among others, recommended or restricted nemolizumab, while NICE (England) and NYE METODER (Norway) did not recommend it.
Every record falls within a 1.2-year window, 25 Jun 2025 to 9 Sep 2026 — a compressed review cycle.
PBAC (Australia) changed its position: not recommended in 2025, recommended by 2026, after a resubmission.
No assessment is on file from PHARMAC (New Zealand) and TLV (Sweden), each among the eight highest-volume agencies here.
The file is active: 17 of 18 records date from 2023 or later.
6 distinct indication wordings are recorded for nemolizumab by the agencies that label one in English (AWMSG, NICE, PBAC and SMC).
2 of these 18 records carry a year of decision but no day, so any interval quoted here is approximate to within a year.
HAS (France) was first to assess nemolizumab, on 25 Jun 2025; AWMSG (Wales) did not open a file until 28 Jul 2026 — a moderate spread of 1.1 years between the earliest and latest system to look at it.
Activity is concentrated rather than steady: 10 of 17 dated records fall in 2025 alone.
7 of the 11 agencies here assessed nemolizumab more than once, NICE (England) most often at 2 entries — repeat review is the norm for this molecule rather than the exception.
11 of the 18 agencies in this archive hold a record for nemolizumab.
The full ledger for nemolizumab reads 6 recommended, 5 not recommended, 2 deferred to NICE and 2 restricted, with 3 in other categories.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| AWMSG (Wales) | 28 Jul 2026 | Treatment of adults with moderate-to-severe prurigo nodularis who are candidates for systemic therapy | excluded, NICE appraised | source |
| HIRA (South Korea) | 2 Jul 2026 | 아토피 피부염 전신요법의 대상이 되는 12 세 이상의 청소년 및 성인에서 국소 치료제로 적절히 조절되지 않거나 이들 치료제가 권장되지 않는 중등도에서 중증 아토피 피부염의 치료 | reimbursable only at the evaluated price | source |
| PBAC (Australia) | 2026 | Atopic dermatitis | Recommended | source |
| SMC (Scotland) | 11 May 2026 | Treatment of adults with moderate-to-severe prurigo nodularis (PN) who are candidates for systemic therapy. | not recommended | source |
| CIPM (Spain) | 28 Apr 2026 | LABORATORIO MEDICAMENTO FORMATO CN Precio € Criterios para la financiación PURPOSE PHARMA INTERNATIONAL AB ATTROGY 250 M… | financed by the SNS | source |
13 further decisions for nemolizumab, across 9 agencies, are not shown here. They include the most recent record on file, 9 Sep 2026 from NICE (England); its outcome is in the subscriber dataset. They link to 11 further source documents.
Related molecules
- dupilumab — same ATC class D11A — Other dermatologicals
- abrocitinib — same ATC class D11A — Other dermatologicals
- lebrikizumab — same ATC class D11A — Other dermatologicals
- delgocitinib — same ATC class D11A — Other dermatologicals
- diclofenac — same ATC class D11A — Other dermatologicals
- ivermectin — same ATC class D11A — Other dermatologicals
Coverage: 18 decisions for nemolizumab from 11 agencies, 2025 to 2026. Data to 7 Sep 2026. ATC class D11A — Other dermatologicals. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.